IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3314
Positioning
Market Dominance
Services
Healthcare
$2.1B
Brian F. Sullivan
Celcuity Inc. focuses on the development of molecularly targeted therapies for cancer patients in the United States. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3k signaling activity in breast and ovarian tumor cells.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = CELC ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | 21.3% | 18.6% | 64.5% | 35.7% | 39.5% | 6.5% | 0.0% | 0.0x | $644M | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | 15.4% | 12.6% | 38.7% | 17.1% | 17.0% | -39.7% | 0.0% | 0.0x | $439M | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 28.1% | 16.8% | 48.1% | 23.8% | 18.5% | 78.6% | 0.0% | 37.0x | $220M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | 12.4% | 2.9% | 100.0% | 28.2% | 26.2% | 5.5% | 0.8% | 264.0x | $19.4B | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.6% | 7.8% | 43.8% | 7.4% | 5.9% | 31.2% | 0.0% | 0.0x | $857M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 18.0% | 4.6% | 97.3% | 52.2% | 32.7% | -3.4% | 0.0% | 271.0x | $8.0B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | 9.4% | 4.9% | 55.5% | 8.7% | 7.7% | 13.6% | 1.3% | 7.0x | $78.0B | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | 22.1% | 15.6% | 62.5% | 28.1% | 28.7% | -1.0% | 2.8% | 9.0x | $56.6B | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 21.4% | 8.0% | 100.0% | 10.0% | 7.5% | 14.1% | 0.0% | 27.0x | $1.8B | VS | |
$CELC Celcuity Inc. | 42 | 15 | 28 | 94 | - | - | -133.3% | -32.7% | - | - | - | - | 0.0% | 117.0x | $2.1B | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.3% | 1.9% | 59.6% | 3.5% | 2.3% | 7.8% | 0.0% | 0.3x | - | REF |
Celcuity Inc. (CELC) receives a "Reduce" rating with a composite score of 41.8/100. It ranks #3314 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Brian F. Sullivan
Chief Executive Officer
Labor Force
40
15
25
43
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for CELC
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CELC.
View All RatingsInsufficient data for Financial Analysis
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 15 | 0 | +15ALPHA |
| MOMENTUM | 94 | 98 | -4NEUTRAL |
| VALUATION | 28 | 21 | +7ALPHA |
| INVESTMENT | 25 | 14 | +11ALPHA |
| STABILITY | 43 | 42 | +1NEUTRAL |
| SHORT INT | 16 | 2 | +14ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -53.8% vs WACC 9.6% (spread -63.3%)
GM N/A vs sector 60%, OM N/A vs sector 4%
Capital turnover 0.00x
Rev growth N/A, 9yr history
Interest coverage -9.3x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Celcuity Inc. receives a Reduce rating from our analysis, with a composite score of 41.8/100 and 2 out of 5 stars, ranking #3314 out of 7,333 stocks. CELC's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
Celcuity Inc. registers a weak quality score of just 15/100, indicating significant profitability challenges. The company reports a return on equity of -133.3% (sector avg: 5.3%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
CELC registers a value score of just 28/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 41.46x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Celcuity Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -32.7% (sector: 1.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Celcuity Inc. (CELC) is exhibiting exceptional momentum with a score of 94/100, placing it among the strongest trending stocks in the market. Revenue growth data is not currently available, while a beta of 1.05 reflects its sensitivity to broader market moves. Stocks with momentum scores this high have historically outperformed over the following 3–12 months, suggesting CELC may continue to benefit from strong institutional interest and positive price trends.
CELC's stability score of 43/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.05 and a debt-to-equity ratio of 117.00x (sector avg: 0.3x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Celcuity Inc.'s short interest score of 16/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 117.00x). At $2.1B (mid-cap), CELC carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Celcuity Inc. is a mid-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #3314 of 7,333 overall (55th percentile). Key comparisons include ROE of -133.3% trailing the 5.3% sector median. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While CELC currently exhibits a REDUCE profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (15) would have the largest impact on the composite score.
ROE 2610% BELOW SECTOR MEDIAN
Debt/Equity 46700% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Celcuity Inc. (CELC) as a Reduce with a composite score of 41.8/100 at a current price of $105.68. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (94th percentile) and stability (43th percentile), which together account for the majority of the composite score. Offsetting weakness in quality (15th percentile) and investment (25th percentile) tempers our overall conviction. We assign a No Moat rating (13/100), High uncertainty, and Poor capital allocation.
Key items to watch: balance sheet deleveraging progress; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Celcuity Inc. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 41.8/100 places it at rank #3314 in our full 7,333-stock universe. At $2.1B in market capitalization, Celcuity Inc. is a mid-cap player in the Services space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (94th percentile) are constructive regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for Celcuity Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $105.68, Celcuity Inc. is trading at a premium to fundamental value. Our value factor score of 28/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 41.5x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Positive momentum (94th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
The Reduce rating (composite 41.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (117% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Below-average quality (15th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a High uncertainty rating to Celcuity Inc.. Key risk factors include significant leverage (117% debt-to-equity), weak quality scores (15th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: significant leverage (117% debt-to-equity); weak quality scores (15th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 43th percentile and quality factor at the 15th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate Celcuity Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-133.3%), weak asset returns (ROA -32.7%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Celcuity Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Celcuity Inc. receives a Reduce rating with a composite score of 41.8/100 (rank #3314 of 7,333). Our quantitative framework assigns a No Moat (13/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 41/100.
Our analysis does not support a constructive view on Celcuity Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Celcuity Inc. a meaningful economic moat, scoring 13/100 on our composite assessment. The ROIC-WACC spread of -63.3% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and financial resilience (2.9/20). GM N/A vs sector 60%, OM N/A vs sector 4%. Interest coverage -9.3x. These pillars form the core of Celcuity Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and reinvestment efficiency (0/20). ROIC -53.8% vs WACC 9.6% (spread -63.3%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Celcuity Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 15/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -133.3% and ROA of -32.7%. Relative to the Services sector, sector comparison data is limited, and ROE of -133.3% compares to a sector median of 5.3%.
The balance sheet reflects above-average leverage with D/E of 117%. The sector median D/E is 0%, putting Celcuity Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Celcuity (NasdaqCM:CELC) has appointed Charles (Chip) R. Romp to its Board of Directors. Romp brings extensive oncology commercialization experience from senior roles at Seagen and Genentech. The appointment comes as Celcuity advances Gedatolisib in collaboration with Pfizer. Celcuity, trading at $105.15, has seen very large share price gains over the past year, with a 1 year return above 800% and a 3 year return above 800% as well. Short term moves have been more mixed, with a 0.6% return...
Celcuity Inc. recently appointed Charles (Chip) R. Romp, a veteran oncology-focused pharmaceutical executive and current CEO of Secura Bio, to its Board of Directors, adding more than 25 years of commercial and sales leadership experience to the company. Romp’s track record helping build commercial franchises for oncology drugs at Seagen and Genentech adds board-level insight that aligns directly with Celcuity’s focus on bringing targeted cancer therapies to market. We’ll now look at how...
Celcuity Inc. recently appointed Charles (Chip) R. Romp, a veteran oncology commercial leader and current CEO of Secura Bio, to its Board of Directors, adding deep pharmaceutical sales and commercialization expertise to its governance team. Romp’s experience building commercial franchises at Seagen and Genentech across key oncology brands could meaningfully shape how Celcuity prepares for potential future product launches and market positioning. We’ll now examine how Romp’s extensive...

Perceptive Advisors purchased 203,881 shares of Celcuity (CELC) in Q4 2025 for approximately $16.76 million, bringing its stake to 5.62% of AUM and making it the fund's second-largest holding. The stock has surged 700% over the past year, driven by anticipation of FDA approval for the company's lead drug candidate Gedatolisib, which has a PDUFA goal date of July 17, 2026. The significant investment by a specialist biotech investor suggests conviction that major catalysts remain ahead.
Celcuity director David Dalvey sold 20,000 shares indirectly for $2.4 million on January 27, 2026, representing 18.18% of his holdings. The sale occurred via a Rule 10b5-1 trading plan through Brightstone Venture Capital Fund. Despite the insider sale, Celcuity stock has surged 933% over the past year following positive clinical trial results for its breast cancer treatment, though the company remains unprofitable.